europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

Interview with Bill Nankervis, Executive Vice President and Chief Operating Officer, Lallemand Group of Companies

18/05/2021
INTERVIEW
Bill Nankervis

About Bill Nankervis

Bill holds a BSc in Mechanical Engineering and started his career in the chemical industry in South Africa and the UK (for ICI) before joining Anchor Yeast in South Africa. He relocated to the USA in 2007 to lead Lallemand’s Biofuels & Distilled Spirits business and, in 2011, he resettled in France (Toulouse) to assume leadership of the Specialties Division of the Group. He moved back to North America in 2014 in preparation for taking on the role of Executive VP & COO responsible for all business units and operations worldwide.

Interview with... Bill Nankervis, Executive Vice President and Chief Operating Officer, Lallemand Group of Companies

1) Lallemand is poised at an exciting time for industrial biotechnology – where do you see your greatest opportunities?
At Lallemand we are passionate about Yeast and Bacteria and about Biotechnology in general. We are fortunate that there are so many opportunities for further development in applications for yeast, bacteria and their derivatives. We have organised ourselves to be able to bring focus to different market areas and have more than 10 business units, each dedicated to researching, developing, producing and marketing products and solutions for customers and partners operating within those markets. We have big dreams about the future potential and I honestly believe each of these units is still in the development phase of what we can imagine delivering in future. Addressing the environment and climate crisis, improving plant health and productivity, food security and safety (with bio-preservation for example), animal and human health are all areas of great opportunity in addition to the more traditional food ingredient and beverage industries.

2) How has the company changed over the years as technologies advance?
We strive to be one of the leading players in all the areas that we chose to put effort and focus into. We are fortunate that this approach and the opportunities in the Biotechnology space have allowed us a long track record of growth as a Group.

Naturally this brings a lot of change over the years! Key to supporting this is ongoing reinvestment in our capabilities. Human resources are the most important in that respect and I am proud to be one of the leaders of a tremendously talented, committed and diverse team around the World. In addition, funding ongoing research and development, both internally and with key partners, as well as investment in production capacity and the supply chain that goes with that make us a significantly different organisation than just 10 years ago. Our core values, passion and vision however remain unchanged.

3) How is Lallemand planning to grow in Europe?
Our growth is driven by listening to our customers and partners and a willingness “to try”. Even if we do not have a ready solution, perhaps it is possible if we just try! That ethos and not fearing failure, using customer complaints as one vector for innovation (for example) is applied not only in Europe but across all our businesses around the World. I am convinced there remain many opportunities in Europe and we will continue to look for those that are right for us and invest accordingly.

We are encouraged by the European Commission’s Green Deal ambitions turning challenges into opportunities and ensuring a sustainable future economy. It is essential that there is an appropriate framework in Europe to encourage ongoing investment and innovation in Biotechnology if we hope to realise all the potential benefits Industrial Biotechnology has to offer our World.

4) How is your skills profile changing as the company grows?
Encouraging an entrepreneurial and innovative spirit and the ability to work both autonomously and in teams continues to be essential for Lallemand. Similarly developing young people who will ensure our future success. Skills profiles have changed as we have grown and will continue to evolve with the digital age and the need for specific new kinds of skills as technology develops.

Website Size (7)

Interview with Lallemand


Download
2021_05_G_O_Interview-with-LallemandDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
07/03/2023

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more
01/03/2023

Vlad Olteanu new Healthcare Public Affairs Director at EuropaBio


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies